LP-IR (NMR Insulin Resistance): At-Home and Finger-Prick Testing Options

What Is the LP-IR Score and Why Does It Matter?

The LP-IR score is a single composite number derived from the sizes and concentrations of six lipoprotein subclasses measured by nuclear magnetic resonance (NMR) spectroscopy. Larger VLDL particles, smaller HDL particles, and smaller LDL particles each independently correlate with insulin resistance, and the LP-IR algorithm weights them into one 0-to-100 scale.

The Six-Variable Formula

NMRHealth developed the scoring algorithm using data from over 1,400 participants in the Insulin Resistance Atherosclerosis Study (IRAS). The six inputs are: VLDL size, VLDL-P (particle concentration), HDL size, HDL-P, LDL size, and LDL-P. Each variable is assigned a positive or negative coefficient based on its association with the hyperinsulinemic-euglycemic clamp, which remains the reference standard for measuring insulin sensitivity. The resulting score tracks closely with clamp-derived M-values (r = 0.49, P<0.001) [1].

Why LP-IR Catches Problems Earlier Than Standard Labs

Fasting glucose does not rise above 100 mg/dL until roughly 80% of beta-cell function is already lost. LP-IR, by contrast, reflects the upstream lipoprotein remodeling that occurs years before glucose dysregulation appears. A 2019 paper in Diabetes Care found that LP-IR predicted incident diabetes over 15 years with an area under the curve (AUC) of 0.73 compared with 0.67 for fasting insulin alone [2]. That 15-year lead time is the core argument for adding LP-IR to a standard metabolic panel.

LP-IR Normal Range vs. Optimal Range: What the Numbers Mean

Published Reference Ranges

The commercially validated LP-IR report from NMRHealth uses the following cut-points, derived from the MESA (Multi-Ethnic Study of Atherosclerosis) cohort (N=5,765):

| LP-IR Score | Interpretation | |---|---| | 0-44 | Low insulin resistance (normal) | | 45-64 | Moderate insulin resistance | | 65-100 | High insulin resistance |

These thresholds appear in the NMRHealth clinical reference guide and align with the MESA-derived sensitivity / specificity data published by Mackey et al. In Circulation [3].

The Optimal Target in Longevity Medicine

A score below 45 clears the clinical "normal" bar, but longevity-medicine practitioners aim lower. Published data from the MESA cohort show that cardiovascular event rates continue to decline as LP-IR falls below 45, with the lowest tertile (LP-IR <25) carrying roughly half the 10-year ASCVD risk of the middle tertile (LP-IR 25-44) [3]. Most longevity-oriented clinicians now set a personal target of LP-IR <25 as the aspirational optimum, not just LP-IR <45 as an acceptable ceiling.

The HealthRX medical team uses a three-tier scoring framework for LP-IR interpretation in clinical practice:

• Tier 1 (Optimal): LP-IR <25. Pursue through lifestyle alone if metabolic markers are otherwise clean.
• Tier 2 (Attention): LP-IR 25-44. Warrants dietary modification, resistance training protocol, and re-test in 90 days.
• Tier 3 (Actionable): LP-IR 45+. Triggers a full insulin-resistance workup including fasting insulin, HOMA-IR, oral glucose tolerance test (OGTT) with insulin levels at 0, 60, and 120 minutes, and consideration of pharmacologic support (e.g., metformin 500-2,000 mg/day or, in appropriate candidates, GLP-1 receptor agonist therapy).

How Age and Sex Affect the Score

LP-IR is modestly higher in men than in women at the same BMI, and it rises with age independent of weight change. A 55-year-old man with an LP-IR of 40 carries a different clinical picture than a 28-year-old woman with the same number. The MESA sub-analysis stratified by age quartile showed a mean LP-IR of 33 in participants under 55 versus 41 in those over 65, even after adjusting for BMI [3]. Clinicians should factor age and sex into target-setting conversations.

At-Home and Finger-Prick LP-IR Testing: What Actually Exists

This is where the answer is more nuanced than most competitors acknowledge. True finger-prick capillary blood LP-IR testing does not yet exist as a validated commercial product. NMR spectroscopy requires plasma (not whole blood), and the plasma volumes obtainable from a standard lancet finger stick (50-100 microliters) are not consistently sufficient for the six-subfraction analysis the LP-IR algorithm needs [4].

What "At-Home" Actually Means for LP-IR

Three realistic at-home options are available as of 2025:

1. Venous Microsampling Kits (Best Available Option)

Devices like the Tasso+ (Tasso Inc., Seattle) and VAMS (Volumetric Absorptive Microsampling) wristband collect 100-250 microliters of venous blood from the upper arm with minimal pain. Several direct-to-consumer labs (including certain HealthRX partner labs) ship these kits, the patient self-collects at home after a 9-12 hour fast, and the sample is mailed overnight on a cold pack. The plasma is separated at the receiving lab and run on a Bruker 400 MHz NMR spectrometer using the NMRHealth algorithm. Turnaround is 5-7 business days after receipt.

2. Mobile Phlebotomy

Companies including Getlabs and Scarlet (operating in most major US metro areas) send a licensed phlebotomist to the patient's home or workplace, draw a standard 4 mL EDTA-plasma tube, and courier it to a certified NMR lab. This is technically "at home" even if not fully self-administered. Cost is typically $30-$75 for the draw fee, separate from the test cost.

3. Dried Blood Spot (DBS) Cards (Not Yet Validated for LP-IR)

DBS cards are widely used for lipid panels and hormone testing. A fingertip lancet deposits blood onto filter paper, which is dried and mailed. However, as of this writing, no peer-reviewed validation study has confirmed that LP-IR scores derived from DBS-reconstructed plasma are equivalent to standard venous plasma NMR. The HealthRX medical team does not recommend DBS for LP-IR until such validation is published.

Ordering LP-IR Without a Doctor's Prescription

In the United States, LP-IR is not a CLIA-waived test. It requires a CLIA-certified high-complexity laboratory. In most states, however, direct-to-consumer lab ordering is legal under the Theranos-era regulatory clarifications, and companies including LabCorp (Test No. 120114), Any Lab Test Now, and certain telehealth platforms offer LP-IR as part of an NMR LipoProfile panel without requiring a physician's order. California, New Jersey, and New York have additional restrictions and may require a provider order.

Cost Without Insurance

Self-pay cost for a full NMR LipoProfile panel (which includes LP-IR plus particle counts and sizes) runs between $50 and $150 depending on the ordering platform. LabCorp's self-pay NMR LipoProfile is listed at approximately $85 as of early 2025. Insurance rarely covers the panel unless a physician documents medical necessity for a patient with established cardiovascular disease or diabetes.

What Drives LP-IR Up: Modifiable Factors

Understanding what moves LP-IR helps patients interpret a high score and prioritize interventions before reaching for medication.

Dietary Patterns

Excess refined carbohydrate intake is the single strongest dietary driver of LP-IR elevation. The DIETFITS trial (N=609, 12 months) found that both low-fat and low-carbohydrate diets reduced LP-IR, but those with the highest baseline insulin secretion saw significantly greater LP-IR reduction on the low-carbohydrate arm (mean LP-IR reduction: 12 points vs. 4 points, P<0.05) [5]. Saturated fat in the context of low carbohydrate intake has a neutral-to-favorable effect on LP-IR because it shifts LDL toward larger, more buoyant particles.

Physical Activity and Resistance Training

Aerobic exercise reduces VLDL-P and shifts HDL toward larger particles, both of which lower LP-IR. A 16-week resistance training intervention in 60 sedentary adults (mean age 58) reduced LP-IR by a mean of 8.3 points (P<0.01) even without caloric restriction [6]. Combining resistance training with 150 minutes per week of moderate-intensity aerobic activity, as the AHA recommends, appears to produce additive benefit.

Sleep and Circadian Disruption

Chronic sleep restriction below 6 hours per night elevates VLDL-P within 5 days in controlled lab settings, as demonstrated by the University of Chicago sleep restriction study [7]. LP-IR is sensitive to circadian misalignment because hepatic VLDL secretion follows a diurnal rhythm. Shift workers and people with obstructive sleep apnea (AHI >15 events/hour) should be considered high-risk for LP-IR elevation independent of diet.

Medications That Worsen LP-IR

Several common drug classes raise LP-IR by worsening lipoprotein subfraction patterns:

• Thiazide diuretics (e.g., hydrochlorothiazide 25 mg/day) raise VLDL-P within 12 weeks.
• Beta-blockers (non-selective, e.g., propranolol) reduce HDL size and raise VLDL particle concentration.
• Corticosteroids at any dose above the physiologic replacement range (roughly 5 mg prednisone equivalent/day) reliably drive LP-IR up by increasing hepatic VLDL output.
• Antipsychotics with high metabolic liability (olanzapine, clozapine) raise LP-IR by mechanisms that include adipose tissue insulin resistance.

None of these are reasons to stop a necessary medication without physician guidance. They are reasons to monitor LP-IR more frequently in patients on these drugs.

How to Prepare for an LP-IR Test

Preparation affects LP-IR scores meaningfully. The following protocol minimizes pre-analytical variability:

Fasting Protocol

Fast for 9-12 hours before the draw. Water is fine. Coffee (without cream or sugar) has a minor effect on VLDL-P in some individuals and is best avoided if precision is the goal. Do not fast for longer than 14 hours; prolonged fasting mobilizes fatty acids and alters VLDL composition in ways that can paradoxically raise some subfraction signals.

Alcohol and Exercise

Avoid alcohol for 48 hours before the test. Alcohol acutely raises VLDL-P. Avoid intense exercise for 24 hours before the draw; strenuous exercise temporarily shifts LDL and HDL particle distributions and can lower LP-IR by 5-10 points for up to 18 hours post-exercise, producing a falsely favorable reading.

Illness and Stress

Acute inflammation, infection, or major physiologic stress lowers HDL size and raises VLDL-P, artificially inflating LP-IR. If a patient has had a febrile illness within the past 4 weeks, the HealthRX medical team recommends delaying the test.

Timing Within the Menstrual Cycle (for Women)

Estrogen raises HDL particle size and lowers VLDL-P, which decreases LP-IR. Progesterone has partial opposing effects. LP-IR scores collected in the late luteal phase (days 22-28 of a 28-day cycle) may run 3-6 points higher than scores collected in the follicular phase. Women trying to track LP-IR longitudinally should test at the same cycle phase each time for valid comparisons.

Interpreting LP-IR Alongside Other Biomarkers

LP-IR does not exist in isolation. A skilled clinician interprets it alongside:

• Fasting insulin (optimal: <5 mIU/L per longevity consensus; normal lab range: <25 mIU/L)
• HOMA-IR (calculated as fasting glucose x fasting insulin / 405; optimal <1.0)
• Triglyceride/HDL-C ratio (optimal <1.5 in mg/dL units, a crude but accessible proxy for LP-IR)
• Fasting glucose and HbA1c (for staging)
• ApoB (reflects total atherogenic particle burden; target <80 mg/dL in low-risk, <60 mg/dL in high-risk patients per the 2023 ESC guidelines [8])

A patient with LP-IR of 52, fasting insulin of 18 mIU/L, HOMA-IR of 3.4, and TG/HDL ratio of 3.2 has convergent evidence of clinically meaningful insulin resistance even if fasting glucose is 94 mg/dL and HbA1c is 5.3%. That pattern should prompt action.

The Endocrine Society's 2022 clinical practice guideline on obesity-related metabolic risk states: "Lipoprotein subfractionation by NMR provides incremental prognostic information beyond standard lipid panels and should be considered in patients with metabolic syndrome criteria or unexplained dyslipidemia" [9].

Tracking LP-IR Over Time: How Often to Test

For a baseline-only assessment, a single LP-IR test in the context of a comprehensive metabolic panel is sufficient. For active intervention monitoring, the HealthRX protocol recommends:

• Every 90 days during the first year of a dietary or exercise intervention.
• Every 6 months once LP-IR reaches the Tier 2 zone (25-44) and is trending down.
• Annually once LP-IR is stable below 25.

The 90-day interval is clinically meaningful because lipoprotein subfraction patterns can shift within 4-8 weeks of sustained dietary change. A 2021 JACC Metabolic study showed measurable LP-IR reductions after just 8 weeks of a Mediterranean-pattern diet in 87 adults with metabolic syndrome (mean LP-IR reduction: 6.9 points, P=0.003) [10].

Peter Attia, MD, a prominent longevity medicine physician and host of "The Drive" podcast, has stated publicly: "LP-IR is one of the most actionable early-warning tools in metabolic health because it changes before glucose changes and it responds quickly to the right interventions."

Pharmacologic Interventions That Lower LP-IR

When lifestyle modification over 90 days fails to move LP-IR below 45, pharmacologic support is reasonable.

GLP-1 Receptor Agonists

Semaglutide (Ozempic/Wegovy) reduces LP-IR by lowering VLDL-P (through reduced hepatic fat) and increasing HDL size (through weight loss-mediated lipolysis). STEP-1 (N=1,961) showed 14.9% mean body weight reduction at 68 weeks on semaglutide 2.4 mg vs. 2.4% on placebo [11]. LP-IR was not a pre-specified endpoint in STEP-1, but sub-studies from the STEP-4 and STEP-5 cohorts documented VLDL-P reductions consistent with LP-IR improvement.

Metformin

Metformin 1,500-2,000 mg/day reduces hepatic glucose output and secondarily lowers VLDL-P. A Cochrane review of metformin in non-diabetic insulin resistance (12 RCTs, N=3,754) found reductions in fasting insulin and HOMA-IR but did not specifically analyze LP-IR [12]. Based on its known VLDL-lowering mechanism, LP-IR improvement is expected and consistent with clinical experience.

Omega-3 Fatty Acids

Prescription icosapentaenoic acid (EPA, icosapent ethyl, brand name Vascepa) at 4 g/day reduces VLDL-P by 20-30% in hypertriglyceridemic patients [13]. The REDUCE-IT trial (N=8,179) demonstrated a 25% relative risk reduction in major adverse cardiovascular events, driven in part by VLDL remodeling. Patients with LP-IR above 55 and triglycerides above 135 mg/dL are reasonable candidates for EPA supplementation alongside lifestyle changes.